Seres Therapeutics, Inc. 1S9.F Stock
Seres Therapeutics, Inc. Price Chart
Seres Therapeutics, Inc. 1S9.F Financial and Trading Overview
Seres Therapeutics, Inc. stock price | 0.69 EUR |
Previous Close | 5.35 EUR |
Open | 5.2 EUR |
Bid | 5.2 EUR x 30000 |
Ask | 5.35 EUR x 30000 |
Day's Range | 5.2 - 5.2 EUR |
52 Week Range | 2.58 - 9.04 EUR |
Volume | 1.05K EUR |
Avg. Volume | 162 EUR |
Market Cap | 673.71M EUR |
Beta (5Y Monthly) | 2.63169 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.54 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 20.57 EUR |
1S9.F Valuation Measures
Enterprise Value | 740.44M EUR |
Trailing P/E | N/A |
Forward P/E | -3.8235292 |
PEG Ratio (5 yr expected) | 0.03 |
Price/Sales (ttm) | 131.76349 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 144.815 |
Enterprise Value/EBITDA | -2.905 |
Trading Information
Seres Therapeutics, Inc. Stock Price History
Beta (5Y Monthly) | 2.63169 |
52-Week Change | 117.26% |
S&P500 52-Week Change | 20.43% |
52 Week High | 9.04 EUR |
52 Week Low | 2.58 EUR |
50-Day Moving Average | 4.97 EUR |
200-Day Moving Average | 5.57 EUR |
1S9.F Share Statistics
Avg. Volume (3 month) | 162 EUR |
Avg. Daily Volume (10-Days) | 30 EUR |
Shares Outstanding | 127.9M |
Float | 96.22M |
Short Ratio | N/A |
% Held by Insiders | 6.72% |
% Held by Institutions | 83.81% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -5110.64% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -55.35% |
Return on Equity (ttm) | -1600.16% |
Income Statement
Revenue (ttm) | 5.11M EUR |
Revenue Per Share (ttm) | 0.04 EUR |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | -165792000 EUR |
EBITDA | -254848000 EUR |
Net Income Avi to Common (ttm) | -264707008 EUR |
Diluted EPS (ttm) | -2.11 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 106.54M EUR |
Total Cash Per Share (mrq) | 0.83 EUR |
Total Debt (mrq) | 162.71M EUR |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 1.819 |
Book Value Per Share (mrq) | -0.378 |
Cash Flow Statement
Operating Cash Flow (ttm) | -238955008 EUR |
Levered Free Cash Flow (ttm) | -154958880 EUR |
Profile of Seres Therapeutics, Inc.
Country | Germany |
State | MA |
City | Cambridge |
Address | 200 Sidney Street |
ZIP | 02139 |
Phone | 617 945 9626 |
Website | https://www.serestherapeutics.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 431 |
Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is SER-109, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes SER-109 product candidate, which is developed for the treatment of CDI and recurrent CDI; collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease; research collaboration and option agreement with AstraZeneca Inc. for research and develop of microbiome in certain cancers and cancer immunotherapies, including research program for SER-401 targeting various cancers. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Q&A For Seres Therapeutics, Inc. Stock
What is a current 1S9.F stock price?
Seres Therapeutics, Inc. 1S9.F stock price today per share is 0.69 EUR.
How to purchase Seres Therapeutics, Inc. stock?
You can buy 1S9.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Seres Therapeutics, Inc.?
The stock symbol or ticker of Seres Therapeutics, Inc. is 1S9.F.
Which industry does the Seres Therapeutics, Inc. company belong to?
The Seres Therapeutics, Inc. industry is Biotechnology.
How many shares does Seres Therapeutics, Inc. have in circulation?
The max supply of Seres Therapeutics, Inc. shares is 154.74M.
What is Seres Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Seres Therapeutics, Inc. PE Ratio is now.
What was Seres Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Seres Therapeutics, Inc. EPS is -0.54 EUR over the trailing 12 months.
Which sector does the Seres Therapeutics, Inc. company belong to?
The Seres Therapeutics, Inc. sector is Healthcare.